JPMorgan Chase & Co. Reports 4.9% Ownership in Karyopharm Therapeutics Inc.

JPMorgan Chase & Co. has filed an amendment to its Schedule 13G, reporting a 4.9% ownership in Karyopharm Therapeutics Inc. The filing indicates that JPMorgan Chase & Co. holds 427,624 shares of common stock, with sole voting and dispositive power over these shares. The filing also confirms that the securities were acquired and are held in the ordinary course of business, and not for the purpose of influencing the control of the issuer. The amendment was signed by Rachel Tsvaygoft, Vice President, on behalf of JPMorgan Chase & Co. The filing is categorized as a Schedule 13G/A, which is used to report beneficial ownership of more than 5% of a class of equity securities, but in this case, the ownership is reported as 4.9%.